C-reactive protein independently predicts HIV-related outcomes among women and children in a resource-poor setting.
about
Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010Role of high-sensitivity C-reactive protein measurements in HIV patientsActivation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.Effect of multiple micronutrient supplementation on survival of HIV-infected children in Uganda: a randomized, controlled trial.C-reactive protein levels increase during HIV-1 disease progression in Rakai, Uganda, despite the absence of microbial translocation.Modified Kigali combined staging predicts risk of mortality in HIV-infected adults in Lusaka, Zambia.Pre-antiretroviral therapy serum selenium concentrations predict WHO stages 3, 4 or death but not virologic failure post-antiretroviral therapy.Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals.Nutrition and inflammation serum biomarkers are associated with 12-week mortality among malnourished adults initiating antiretroviral therapy in ZambiaC-reactive protein (CRP), interferon gamma-inducible protein 10 (IP-10), and lipopolysaccharide (LPS) are associated with risk of tuberculosis after initiation of antiretroviral therapy in resource-limited settings.Immune activation markers in peripartum women in Botswana: association with feeding strategy and maternal morbidity.Concurrent Anemia and Elevated C-Reactive Protein Predicts HIV Clinical Treatment Failure, Including Tuberculosis, After Antiretroviral Therapy InitiationPre-cART Elevation of CRP and CD4+ T-Cell Immune Activation Associated With HIV Clinical Progression in a Multinational Case-Cohort StudyPersistently Elevated C-Reactive Protein Level in the First Year of Antiretroviral Therapy, Despite Virologic Suppression, Is Associated With HIV Disease Progression in Resource-Constrained Settings.Biomarkers of inflammation in HIV-infected Peruvian men and women before and during suppressive antiretroviral therapy.Evaluating health and disease in Sub-Saharan Africa: minimally invasive collection of plasma in the Malawi Longitudinal Study of Families and Health (MLSFH)Diagnostic and prognostic value of serum C-reactive protein for screening for HIV-associated tuberculosisTreatment interruption after pregnancy: effects on disease progression and laboratory findingsHighly sensitive C-reactive protein, body mass index, and serum lipids in HIV-infected persons receiving antiretroviral therapy: a longitudinal study.Weight status and associated factors among HIV infected people on antiretroviral therapy in rural Dikgale, Limpopo, South Africa.Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202Diagnostic accuracy and clinical role of rapid C-reactive protein testing in HIV-infected individuals with presumed tuberculosis in South Africa.Sex-Related Differences in Inflammatory and Immune Activation Markers Before and After Combined Antiretroviral Therapy Initiation.Predictive value of C-reactive protein for tuberculosis, bloodstream infection or death among HIV-infected individuals with chronic, non-specific symptoms and negative sputum smear microscopy.Intestinal barrier dysfunction and microbial translocation in HIV-infected pregnant women is associated with preterm birth.
P2860
Q27690715-82707395-0AD8-4173-90D3-0537A93DD93DQ28067891-903F4AA0-65D8-4F6C-B3C2-55BBAE43EBC4Q33943429-E3C3DE3D-7DB5-4B6D-B5EF-0D2C37432732Q33948636-BD468067-7A2C-4415-88D0-293C95B3E2CAQ34012387-03B36A64-DC32-418C-AEFA-29CD9D07E51FQ34085355-EBCE54B4-0678-430C-A16C-729A0E256C05Q34578091-173C4958-4B9A-4C42-90C9-B0D605ADDE9CQ34875287-F8DD61E9-B49B-41EE-849E-97A8473A507EQ34980769-06B86FAA-1279-4B7E-844C-F39963DA2690Q35125891-9FEBEB5E-A24E-4593-9707-4FCC0FFB3B4FQ35127830-01746CDC-8F68-48DD-906C-9A4E14F6CF1EQ35975559-0D4FD95A-DDDC-4F76-B135-1F7B3BD254EDQ36068935-0E0AFB12-49A7-444B-86E2-53946433403AQ36654575-EABF0484-B2CD-478E-8112-267EE1DD54C0Q36775142-6C51EBED-764F-43D4-8F55-58A1D3BD226EQ37190568-4577B2A0-7F1C-4E11-A5C1-16137444C194Q37275878-872FCDE8-690E-4E50-912C-D5487DA474C7Q37409196-8D95EF97-DFAF-4429-B453-B2E03DACE0FDQ37478992-C4325997-F6E3-4B7A-8611-339BC762C6A1Q37496832-C94BE1DD-C33D-43ED-9F17-2AE4858C6D18Q37619346-62FCF943-E88D-43CF-A5E4-53178C698B65Q37732966-3E5F1D48-49BD-4A68-BF05-97CF2F800AD9Q38858603-41132B2C-C7AE-4AF9-98F3-2B47A0F788D9Q47290743-133E18F0-D7D6-4751-8FDC-9135A8AEF670Q54246777-08B91479-0105-49A5-90A3-08FD975D3A5D
P2860
C-reactive protein independently predicts HIV-related outcomes among women and children in a resource-poor setting.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
C-reactive protein independent ...... en in a resource-poor setting.
@en
C-reactive protein independent ...... en in a resource-poor setting.
@nl
type
label
C-reactive protein independent ...... en in a resource-poor setting.
@en
C-reactive protein independent ...... en in a resource-poor setting.
@nl
prefLabel
C-reactive protein independent ...... en in a resource-poor setting.
@en
C-reactive protein independent ...... en in a resource-poor setting.
@nl
P2860
P50
P1433
P1476
C-reactive protein independent ...... en in a resource-poor setting.
@en
P2093
Roland Kupka
P2860
P304
P356
10.1097/QAD.0B013E32826FB6C7
P407
P577
2007-10-01T00:00:00Z